In breast cancer and gastric carcinoma, silencing CAB39L facilitated G1/S phase transition and reduced cell apoptosis and thus promoted tumor progression, while overexpression of CAB39L exerted opposite effects [11,12]. Here, CAB39L is linked to neoplasm.